Despite the widespread use of non-vitamin KaEurodependent oral anticoagulants (NOAC), recommendations from regulatory agencies and interdisciplinary expert panels on handling bleeding situations with NOAC, uncertainty in dealing with these situations still exists especially in hospitals with a low emphasis on hemostatics. In cases of mild bleeding from a clinical perspective, medical surveillance of these patients and delay of the next intake or temporary discontinuation are recommended. In cases of moderate to severe bleeding, the primary measures are focused on stabilization of cardiopulmonary and circulatory functions and simultaneously on the treatment, depending on the localization of the source of bleeding. In cases of life-threatening bleeding, such as intracranial hemorrhage, special hemostatic management is necessary in addition to hemodynamic stabilization measures, which should predominantly be oriented to the clinical severity.